Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036898 | 0.96 | NPC1 (0.41) | NPC1SLC2A1ALDH1A1TSHRLPAR3 | |
| SCHEMBL3933992 | 0.94 | NPC1 (0.44) | NPC1SLC2A1ALDH1A1TSHR | |
| SCHEMBL3946956 | 0.94 | NPC1 (0.44) | NPC1SLC2A1ALDH1A1TSHR | |
| SCHEMBL3943932 | 0.93 | — | — | |
| SCHEMBL31267671 | 0.89 | NPC1 (0.39) | NPC1SLC2A1ALDH1A1TSHRLPAR3 | |
| SCHEMBL31267589 | 0.88 | NPC1 (0.42) | NPC1SLC2A1ALDH1A1TSHRLPAR3 | |
| SCHEMBL28456109 | 0.84 | SLC2A1 (0.33) | SLC2A1 | |
| SCHEMBL28459723 | 0.83 | SLC2A1 (0.37) | SLC2A1ALDH1A1TSHRLPAR3LPAR2 | |
| SCHEMBL19339307 | 0.80 | — | — | |
| SCHEMBL8116098 | 0.80 | NPC1 (0.47) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110206757-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-08-25 | — | — | US | disclosed |
| US-7854934-B2 | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2009021980-A1 | α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025669-A1 | Alpha-alkyl substituted N-acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009016253-A2 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071453-A1 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1932831-A1 | 1,2-Diarylacetylene Derivatives of Acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1912970-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069328-A1 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | NPC1 1531/4885SLC2A1 3749/4885ALDH1A1 3116/4885 |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | FSHR, GNRHR, HNMT | NPC1 2639/4885SLC2A1 3411/4885ALDH1A1 4226/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | NPC1 2801/4885SLC2A1 4126/4885ALDH1A1 3513/4885 |
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | NPC1 2904/4885SLC2A1 3133/4885ALDH1A1 3830/4885 |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | FSHR, GNRHR, CYP19A1 | NPC1 1979/4885SLC2A1 3528/4885ALDH1A1 2364/4885 |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | NPC1 2833/4885SLC2A1 3584/4885ALDH1A1 388/4885 |
| US-20110206757-A1 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF | SIGLEC7, B3GAT3, FUT6 | NPC1 970/4885SLC2A1 1155/4885ALDH1A1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.